Source link : https://www.newshealth.biz/health-news/study-reports-real-world-pembrolizumab-toxicity-in-tnbc/
TOPLINE: In a real-world diverse population of patients with early triple-negative breast cancer (TNBC), 34% of patients who received pembrolizumab developed immune-related adverse events — findings that are comparable, overall, to those from the landmark KEYNOTE-522 trial. However, there were some differences, including higher rates of gastrointestinal (GI) immune-related adverse events, some of which were […]
Author : News Health
Publish date : 2024-11-06 10:11:43
Copyright for syndicated content belongs to the linked Source.
inHealth